Logo

PharmaShots Weekly Snapshots (May 30 – June 03, 2022)

Share this
PharmaShots Weekly Snapshots (May 30 – June 03, 2022)

PharmaShots Weekly Snapshots (May 30 – June 03, 2022)

BMS to Acquire Turning Point for ~$4.1B

Published: June 3, 2022 | Tags: BMS, Acquire, Turning Point Therapeutics, ~$4.1B

Ionis Partner Biogen Report Results of Tofersen in P-III (VALOR) study and OLE to Treat SOD1-ALS

Published: June 3, 2022 | Tags: Ionis, Biogen, Tofersen, P-III, VALOR Study, OLE, SOD1-ALS

InterVenn Biosciences Presents Results of DAWN IO Melanoma as a Novel Liquid Biopsy Test for the Treatment of Cancer at ASCO 2022

Published: June 3, 2022 | Tags: InterVenn Biosciences, DAWN IO Melanoma, Liquid Biopsy Test, Cancer

BMS Reports Results of Orencia (abatacept) in P-III (ACTIV-1) Trial for the Treatment of COVID-19

Published: June 3, 2022 | Tags: BMS, Orencia, abatacept, P-III, ACTIV-1 Trial, COVID-19

Regeneron Entered into Amended and Restated License Agreement with Sanofi for Libtayo (cemiplimab) to Treat Cancer

Published: June 3, 2022 | Tags: Regeneron, Sanofi, Libtayo, cemiplimab, Cancer, VelocImmune technology

Boehringer Ingelheim Entered into a License Agreement with A*STAR to Develop and Commercialize Targeted Cancer Therapies Using Innovative Antibodies

Published: June 3, 2022 | Tags: Boehringer Ingelheim, A*STAR, Antibodies, Cancer

BMS Collaborated with Immatics to Develop Allogeneic Cell Therapy Programs

Published: June 2, 2022 | Tags: BMS, Collaborated with Immatics to Develop Allogeneic Cell Therapy Programs

Takeda’s Revestive (teduglutide) Receives NICE Recommendation for the Treatment of Adults and Children with Short Bowel Syndrome

Published: June 2, 2022 | Tags: Takeda, Revestive, teduglutide, NICE, Recommendation, Short Bowel Syndrome

BMS Presents Results of Deucravacitinib in P-II (PAISLEY) Study for the Treatment of Systemic Lupus Erythematosus at EULAR 2022

Published: June 2, 2022 | Tags: BMS, Deucravacitinib, P-II, PAISLEY Study, Systemic Lupus Erythematosus, EULAR, 2022

Asher Bio Entered into a Clinical Trial Collaboration with Merck to Evaluate AB248 + Keytruda (pembrolizumab) for Locally Advanced or Metastatic Solid Tumors

Published: June 2, 2022 | Tags: Asher Bio, Merck, AB248, Keytruda, pembrolizumab, Solid Tumors

Axsome Publishes Results of AXS-05 (dextromethorphan-bupropion) in P-III (GEMINI) Trial for Major Depressive Disorder in The Journal of Clinical Psychiatry

Published: June 2, 2022 | Tags: Axsome, AXS-05, dextromethorphan-bupropion, P-III, GEMINI Trial, Major Depressive Disorder Journal of Clinical Psychiatry

Repare Entered into a Worldwide License and Collaboration Agreement with Roche to Develop and Commercialize Camonsertib (RP-3500) for Cancers

Published: June 2, 2022 | Tags: Repare, Roche, Camonsertib, RP-3500, Cancers

Janssen Reports Results of Tremfya (guselkumab) in P-III Studies Demonstrated Durable Efficacy Across Joint and Axial Symptoms for Active Psoriatic Arthritis

Published: June 1, 2022 | Tags: Janssen, Tremfya, guselkumab, P-III Studies, Active Psoriatic Arthritis

Astellas Entered into a Research Collaboration and License Agreement with GO Therapeutics to Develop Novel Immuno-Oncology Therapies

Published: June 1, 2022 | Tags: Astellas, GO Therapeutics, Novel, Immuno-Oncology, Therapies, ACCEL Technology

Timber Pharmaceuticals’ TMB-001 Receives the US FDA’s Breakthrough Therapy Designation for the Treatment of Congenital Ichthyosis

Published: June 1, 2022 | Tags: Timber Pharmaceuticals, TMB-001, US, FDA, Breakthrough Therapy Designation, Congenital Ichthyosis

Abbott’s FreeStyle Libre 3 System Receives the US FDA’s Clearance for the Treatment of Diabetes

Published: June 1, 2022 | Tags: Abbott, FreeStyle Libre 3 System, US, FDA, Clearance, Diabetes

Denali Therapeutics and Biogen Initiate P-IIb (LUMA) Study of BIIB122 for the Treatment of Parkinson’s Disease

Published: June 1, 2022 | Tags: Denali Therapeutics, Biogen, P-IIb, LUMA Study, BIIB122, Parkinson’s Disease

BioMarin to Presents Results of in P-I/II Study for the Treatment of Hemophilia A at ISTH 2022

Published: June 1, 2022 | Tags: BioMarin, Valoctocogene Roxaparvovec, P-I/II Study, Hemophilia A, ISTH 2022

Innodem Neurosciences’ ETNA Device Receives the US FDA’s Breakthrough Device Designation for the Treatment of Multiple Sclerosis

Published: May 31, 2022 | Tags: Innodem Neurosciences, ETNA Device, US, FDA, Breakthrough Device Designation, Multiple Sclerosis

Eledon Reports Results of Tegoprubart in P-IIa Trial Demonstrated Safety, Target Engagement, and Biomarker Response for ALS

Published: May 31, 2022 | Tags: Eledon, Tegoprubart, P-IIa Trial, Target Engagement, Biomarker Response, ALS

Regeneron & Sanofi Report the US FDA Acceptance of sBLA for Priority Review of Dupixent (dupilumab) to Treat Prurigo Nodularis

Published: May 31, 2022 | Tags: Regeneron, Sanofi, US, FDA, sBLA, Priority Review, Dupixent, dupilumab, Prurigo Nodularis

GSK to Acquire Affinivax for ~$3.3B

Published: May 31, 2022 | Tags: GSK, Acquire, Affinivax, ~$3.3B

Genentech’s Evrysdi (risdiplam) Receives the US FDA’s Approval for the Treatment of Spinal Muscular Atrophy in Babies Aged Under Two Months

Published: May 31, 2022 | Tags: Genentech, Evrysdi, risdiplam, US, FDA, Approval, Spinal Muscular Atrophy

Pharnext Reports the Completion of Patient Enrollment in the P-III (PREMIER) Trial of PXT3003 for the Treatment of Charcot-Marie-Tooth Disease Type 1A

Published: May 31, 2022 | Tags: Pharnext, P-III, PREMIER Trial, PXT3003, Charcot-Marie-Tooth Disease Type 1A

IASO Biotherapeutics Reports the NMPA’s Acceptance of IND Application for Equecabtagene Autoleucel to Treat Neuromyelitis Optica Spectrum Disorder

Published: May 30, 2022 | Tags: IASO Biotherapeutics, NMPA, IND, Equecabtagene Autoleucel, Neuromyelitis Optica Spectrum Disorder

AstraZeneca Reports the First Patients Dosing of Saphnelo (anifrolumab) in the P-III (IRIS) Trial for the Treatment of Lupus Nephritis

Published: May 30, 2022 | Tags: AstraZeneca, Saphnelo, anifrolumab-fnia, P-III, IRIS Trial, Lupus Nephritis

PharmEnable Entered into a Multi-Target Collaboration with Denali to Discover Therapies for the Treatment of Neurodegenerative Disease

Published: May 30, 2022 | Tags: PharmEnable, Denali, AI Drug Discovery Platform, Neurodegenerative Disease

Novartis’ Kymriah (tisagenlecleucel) CAR-T Cell Therapy Receives the US FDA’s Approval for the Treatment of Follicular Lymphoma

Published: May 30, 2022 | Tags: Novartis, Kymriah, tisagenlecleucel, CAR-T, Cell Therapy, US, FDA, Approval, Follicular Lymphoma

Inovio Presents Results of INO-5401 + INO-9012 & Libtayo (cemiplimab) for the Treatment of Glioblastoma at ASCO 2022

Published: May 30, 2022 | Tags: Inovio, INO-5401, INO-9012, Libtayo, cemiplimab, Glioblastoma, ASCO, 2022

BMS’ Opdivo (nivolumab) + Yervoy (ipilimumab) Receives the US FDA Approval as 1L Treatment for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Published: May 30, 2022 | Tags: BMS, Opdivo, nivolumab, Yervoy, ipilimumab, US, FDA, Approval, Esophageal Squamous Cell Carcinoma

Related Post: PharmaShots Weekly Snapshots (May 23 - 27, 2022)


Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions